Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Vicarious Surgical ( (RBOT) ) is now available.
On April 10, 2025, Vicarious Surgical Inc. received a notice from the New York Stock Exchange (NYSE) for non-compliance with the Minimum Market Capitalization Standard, as its market capitalization and stockholders’ equity both fell below $50 million. The company submitted a Compliance Plan, which was accepted by the NYSE on July 8, 2025, allowing the company 18 months to meet the standards. During this period, the company’s Class A common stock will continue to trade on the NYSE with a “.BC” designation indicating its below-criteria status. This noncompliance does not affect the company’s business operations or SEC reporting requirements.
The most recent analyst rating on (RBOT) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.
Spark’s Take on RBOT Stock
According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.
Vicarious Surgical’s stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.
To see Spark’s full report on RBOT stock, click here.
More about Vicarious Surgical
Average Trading Volume: 14,276
Technical Sentiment Signal: Sell
Current Market Cap: $46.86M
See more insights into RBOT stock on TipRanks’ Stock Analysis page.